ACIU

AC Immune SA (NASDAQ:ACIU) is a Swiss clinical-stage biopharmaceutical company founded in 2003 and headquartered in Lausanne, Switzerland. The company went public on NASDAQ in September 2016. AC Immune specializes in discovering, designing, and developing medicines and diagnostic products for neurodegenerative diseases, particularly those associated with protein misfolding such as Alzheimer's disease, Parkinson's disease, and other related conditions. The company operates through proprietary technology platforms that generate vaccines, antibodies, and small molecules targeting misfolded proteins that accumulate in the brain and cause neurodegeneration.